BioSpace News Archive

Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

Oxford BioTherapeutics announces significant technological advances to its drug discovery platform OGAP® with a new version to be launched at the 14th Annual World ADC Conference in London named OGAP®-Verify.

March 7, 2024
·
6 min read
Drug Development

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

A pioneering Phase 1 CAR T cell therapy trial for the treatment of glioblastoma at City of Hope, one of the largest cancer treatment and research organizations in the United States, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

March 7, 2024
·
8 min read
Biotech Bay

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim announced it will cap out-of-pocket costs at $35 per month for eligible patientsi for all the company’s inhaler products.

March 7, 2024
·
17 min read
Pharm Country

Immunic to Participate in Investor and Scientific Conferences in March 2024

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced participation in the following investor and scientific conferences in March:

March 7, 2024
·
6 min read
Drug Development

NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial

NodThera today announces positive data from its Phase Ib/IIa study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF).

March 7, 2024
·
5 min read
Business

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Foghorn® Therapeutics Inc. today provided a financial update and corporate outlook in conjunction with the Company’s 10-K filing for the year ending December 31, 2023.

March 7, 2024
·
10 min read
Business

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2023, and provided recent operational highlights.

March 7, 2024
·
11 min read
Drug Development

Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis

Alphyn announced today that the second cohort of its Phase 2a trial evaluating zabalafin hydrogel (AB-101a) in patients with atopic dermatitis (AD) and infected AD skin met all endpoints for safety and efficacy.

March 7, 2024
·
5 min read
Business

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2023.

March 7, 2024
·
16 min read
Clene to Present at the 36th Annual ROTH Conference

Clene Inc. today announced that it will participate in the 36th Annual ROTH Conference being held March 18-19, 2024.

March 7, 2024
·
1 min read